Brought to you by:
The essential ‘need’ for vascular surgeons in pulmonary embolism treatment paradigm
The specter of pulmonary embolism (PE) as a common and lethal disease process—with mortality of massive PE static at about 50% for decades while rapid advances were made in stroke and STEMI care—forms the backdrop to a VAM 2023 breakfast…
VQI@VAM: Quality takes center stage at VQI meeting, initiative making much out of zero
Over the past several months, the Society for Vascular Surgery’s Vascular Quality Initiative (VQI) hit some important milestones, including registering procedure number 1,000,000 in its database, enrolling center number 1,000, as well as 100-plus quality charters initiated in 2022. There…
VQI@VAM: Social media helps promote safe technique, study finds
A social media campaign promoting educational videos proved efficient and cost-effective, and similar campaigns will be useful for quality improvement projects directed toward medical trainees. That’s the message from “A social media campaign to promote safe technique in femoral access,”…
BEST-CLI vs. BASIL-2: Different questions yield different answers
Medical editor Malachi Sheahan III, MD, takes a look at seemingly conflicting results from the landmark BEST-CLI and BASIL-2 trials, and asks what they really reveal. This past April, BASIL-2 chief investigator Andrew Bradbury, MD, presented trial results at the…
‘Nobody believed us’: Vascular giant discusses overcoming skeptics to make specialty-defining breakthroughs
Malachi Sheahan III, MD, Vascular Specialist’s medical editor, speaks to living legend and limb-salvage pioneer Frank J. Veith, MD, on the contents of his hard-hitting new book, The Medical Jungle: A Pioneering Surgeon’s Battle to Revolutionize Vascular Care and Challenge…
BASIL-2 and BEST-CLI: A tale of two limb trials
Optimal treatment of patients with chronic limb-threatening ischemia (CLTI) has been an ongoing debate within the vascular community, fueled by growing numbers of patients, evolving technologies, provider bias, and a lack of high-quality evidence. Few randomized controlled trials (RCTs) have…
VAM 2023 beckons
Our annual gathering is almost here. After months of planning, our premiere educational event in vascular surgery, the Vascular Annual Meeting (VAM), opens June 14. Every president before me has said nothing can top this year’s event—and yet, somehow, year…
FDA seeks to ‘modernize’ clinical trials with new draft guidance
The Food and Drug Administration (FDA) has released draft guidance with updated recommendations for good clinical practices (GCPs) aimed at modernizing the design and conduct of clinical trials. In a statement, the regulator said that the updates are intended to…
‘Sonolysis is back’ after safely reducing endarterectomy stroke risk in randomized trial
Positive results from a clinical trial involving a novel therapeutic procedure known as sonolysis—deployed during a carotid endarterectomy (CEA)—were presented at the recent European Stroke Organisation Conference (ESOC; 24–26 May, Munich, Germany). “The randomised clinical trial confirmed the results of…
The top 10 most popular Vascular Specialist stories of May 2023
Last month, Vascular Specialist most piqued reader interest with a commentary from the editor-in-chief on why he supports the decision by the Southern Association for Vascular Surgery (SAVS) to replace its emblem; a guest editorial examining whether physicians nowadays can experience both…